Alpha 2.0
Login Register
» Authors » Anthonet L Koen

Anthonet L Koen

Explore the profile of Anthonet L Koen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 883
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Allergy & Immunology
Top 10 Co-Authors
Shabir A Madhi
Andrew J Pollard
Alane Izu
Clare L Cutland
Lee Fairlie
Teresa Lambe
Gaurav Kwatra
Keertan Dheda
Carmen Briner
Shaun L Barnabas
Published In
N Engl J Med
AIDS
Lancet HIV
Vaccine
Lancet Infect Dis
Affiliations
Soon will be listed here.
Recent Articles
1.
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19
Kaplonek P, Cizmeci D, Kwatra G, Izu A, Shih-Lu Lee J, Bertera H, et al.
Nat Immunol . 2023 Jun; 24(7):1161-1172. PMID: 37322179
Despite the success of COVID-19 vaccines, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern have emerged that can cause breakthrough infections. Although protection against severe disease has been...
2.
Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005)
Koen A, Izu A, Baillie V, Kwatra G, Cutland C, Fairlie L, et al.
Vaccine . 2023 May; 41(23):3486-3492. PMID: 37149443
COVID-19 vaccine efficacy (VE) has been observed to vary against antigenically distinct SARS-CoV-2 variants of concern (VoC). Here we report the final analysis of VE and safety from COV005: a...
3.
T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa
McMahon W, Kwatra G, Izu A, Koen A, Greffrath J, Fairlie L, et al.
AIDS . 2022 Dec; 37(1):105-112. PMID: 36476455
Objectives: This study aimed to investigate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T-cell responses 14 days after single-dose ChAdOx1 nCoV-19 (AZD1222) vaccination in black Africans with and without HIV...
4.
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial
Madhi S, Kwatra G, Richardson S, Koen A, Baillie V, Cutland C, et al.
Lancet Infect Dis . 2022 Oct; 23(3):295-306. PMID: 36273491
Background: COVID-19 vaccine rollout is lagging in Africa, where there has been a high rate of SARS-CoV-2 infection. We aimed to evaluate the effect of SARS-CoV-2 infection before vaccination with...
5.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial
Madhi S, Koen A, Izu A, Fairlie L, Cutland C, Baillie V, et al.
Lancet HIV . 2021 Aug; 8(9):e568-e580. PMID: 34416193
Background: People living with HIV are at an increased risk of fatal outcome when admitted to hospital for severe COVID-19 compared with HIV-negative individuals. We aimed to assess safety and...
6.
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Madhi S, Baillie V, Cutland C, Voysey M, Koen A, Fairlie L, et al.
N Engl J Med . 2021 Mar; 384(20):1885-1898. PMID: 33725432
Background: Assessment of the safety and efficacy of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is investigation of the efficacy of...